Treatment of hepatocellular carcinoma: Present and future

Expert Review of Anticancer Therapy

Volumn 13, Issue 4, 2013, Pages 469-479

  Genco, Chiara ^a   Cabibbo, Giuseppe ^a   Maida, Marcello ^a   Brancatelli, Giuseppe ^a   Galia, Massimo ^a   Alessi, Nicola ^a   Butera, Giuseppe ^a   Genova, Claudio ^a   Romano, Piero ^a   Raineri, Maurizio ^a   Giarratano, Antonello ^a   Midiri, Massimo ^a   Cammà, Calogero ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Barcelona Clinic Cancer Liver Classification; hepatocellular carcinoma; treatment

Indexed keywords

BEVACIZUMAB; BRIVANIB ALANINATE; CISPLATIN; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; IODINATED POPPYSEED OIL; LINIFANIB; MITOMYCIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY GC33; PLACEBO; RAMUCIRUMAB; RAPAMYCIN; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADVANCED CANCER; ANOREXIA; ASTHENIA; CANCER ADJUVANT THERAPY; CANCER PALLIATIVE THERAPY; CANCER PREVENTION; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; COMPARATIVE EFFECTIVENESS; DIARRHEA; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; EARLY INTERVENTION; END STAGE LIVER DISEASE; HAND FOOT SYNDROME; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER TRANSPLANTATION; LIVER TUMOR; MICROWAVE THERAPY; MINIMALLY INVASIVE SURGERY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; TUMOR ABLATION; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; HUMANS; LIVER NEOPLASMS;

EID: 84876146765     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.13.21     Document Type: Review

References (92)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA. Cancer J. Clin. 55(2), 74-108 (2005)
2. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med. 340(10), 745-750 (1999)
3. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann. Intern. Med. 139(10), 817-823 (2003)
4. Sangiovanni A, Del Ninno E, Fasani P et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 126(4), 1005-1014 (2004)
5. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 362(9399), 1907-1917 (2003)
6. EASL European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 56(4), 908-943 (2012)
7. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 53(3), 1020-1022 (2011)
8. Cabibbo G, Craxì A. Hepatocellular cancer: optimal strategies for screening and surveillance. Dig. Dis. 27(2), 142-147 (2009)
9. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J. Hepatol. 48(Suppl. 1), S20-S37 (2008)
10. Piscaglia F, Leoni S, Cabibbo G et al. Cost analysis of recall strategies for non-invasive diagnosis of small hepatocellular carcinoma. Dig. Liver Dis. 42(10), 729-734 (2010)
11. Riaz A, Ryu RK, Kulik LM et al. α-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J. Clin. Oncol. 27(34), 5734-5742 (2009)
12. Chan SL, Mo FK, Johnson PJ et al. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J. Clin. Oncol. 27(3), 446-452 (2009)
13. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 42(5), 1208-1236 (2005)
14. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin. Liver Dis. 19(3), 329-338 (1999)
15. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 134(6), 1752-1763 (2008)
16. Cabibbo G, Enea M, Attanasio M, Bruix J, Craxì A, Cammà C. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 51(4), 1274-1283 (2010)
17. Cabibbo G, Maida M, Genco C et al. Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study. World J. Hepatol. 4(9), 256-261 (2012)
18. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin. Liver Dis. 25(2), 181-200 (2005)
19. Pandey D, Lee KH, Wai CT, Wagholikar G, Tan KC. Long term outcome and prognostic factors for large hepatocellular carcinoma (10 cm or more) after surgical resection. Ann. Surg. Oncol. 14(10), 2817-2823 (2007)
20. Ishii H, Okada S, Nose H et al. Local recurrence of hepatocellular carcinoma after percutaneous ethanol injection. Cancer 77, 1792-1796 (1996
21. Livraghi T, Bolondi L, Lazzaroni S et al. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients. Cancer 69(4), 925-929 (1992
22. Vilana R, Bruix J, Bru C, Ayuso C, Solé M, Rodés J. Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Hepatology 16(2), 353-357 (1992
23. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 210(3), 655-661 (1999)
24. Shiina S, Teratani T, Obi S et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 129(1), 122-130 (2005)
25. Sala M, Llovet JM, Vilana R et al.; Barcelona Clinic Liver Cancer Group. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 40(6), 1352-1360 (2004)
26. Lencioni R, Cioni D, Crocetti L et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology 234(3), 961-967 (2005)
27. Omata M, Tateishi R, Yoshida H, Shiina S. Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: Ethanol injection therapy and radiofrequency ablation. Gastroenterology 127(5 Suppl. 1), S159-S166 (2004)
28. Lencioni R, Crocetti L. Image-guided ablation for hepatocellular carcinoma. Recent Results Cancer Res. 190, 181-194 (2013)
29. Cabibbo G, Craxì A. Needle track seeding following percutaneous procedures for hepatocellular carcinoma. World J. Hepatol. 1(1), 62-66 (2009)
30. Latteri F, Sandonato L, Di Marco V et al. Seeding after radiofrequency ablation of hepatocellular carcinoma in patients with cirrhosis: a prospective study. Dig. Liver Dis. 40(8), 684-689 (2008)
31. Liu DQ, Lu MD, Tan JF et al. [Microwave coagulation at different temperatures for hepatocellular carcinoma management: efficacy evaluation by enzyme histochemical staining]. Nan Fang Yi Ke Da Xue Xue Bao 26, 1149-1151 (2006)
32. Chen MS, Li JQ, Zheng Y et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann. Surg. 243(3), 321-328 (2006)
33. Lencioni R, Crocetti L. Local-regional treatment of hepatocellular carcinoma. Radiology 262(1), 43-58 (2012)
34. Ng KK, Poon RT, Chan SC et al. High-intensity focused ultrasound for hepatocellular carcinoma: a single-center experience. Ann. Surg. 253(5), 981-987 (2011)
35. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med. 334(11), 693-699 (1996
36. Yao FY, Ferrell L, Bass NM et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 33(6), 1394-1403 (2001)
37. Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl. 8(9), 765-774 (2002)
38. Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am. J. Transplant. 7(11), 2587-2596 (2007)
39. Mazzaferro V, Llovet JM, Miceli R et al.; Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 10(1), 35-43 (2009)
40. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 7(3), 462-503 (1954
41. Esnaola NF, Lauwers GY, Mirza NQ et al. Predictors of microvascular invasion in patients with hepatocellular carcinoma who are candidates for orthotopic liver transplantation. J. Gastrointest. Surg. 6(2), 224-32; discussion 232 (2002)
42. Piscaglia F, Bolondi L. The intermediate hepatocellular carcinoma stage: should treatment be expanded? Dig. Liver Dis. 42(Suppl. 3), S258-S263 (2010)
43. Takayasu K, Arii S, Ikai I et al.; Liver Cancer Study Group of Japan. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 131(2), 461-469 (2006)
44. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37(2), 429-442 (2003)
45. Llovet JM, Real MI, Montaña X et al.; Barcelona Liver Cancer Group. Arterial embolisation or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359(9319), 1734-1739 (2002)
46. Lo CM, Ngan H, Tso WK et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35(5), 1164-1171 (2002)
47. Cammà C, Schepis F, Orlando A et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 224(1), 47-54 (2002)
48. Cabibbo G, Genco C, Di Marco V et al. Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolization. Aliment. Pharmacol. Ther. 34(2), 196-204 (2011)
49. Yoo DJ, Kim KM, Jin YJ et al. Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: does transarterial chemoembolization improve survival in these patients? J. Gastroenterol. Hepatol. 26(1), 145-154 (2011)
50. Llovet JM, Ricci S, Mazzaferro V et al.; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359(4), 378-390 (2008)
51. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a Phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10(1), 25-34 (2009)
52. Iavarone M, Cabibbo G, Piscaglia F et al.; SOFIA (SOraFenib Italian Assessment) study group. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology 54(6), 2055-2063 (2011)
53. Cammà C, Cabibbo G, Petta S et al.; on behalf of the WEF and the SOFIA study groups. Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma. Hepatology 57(3), 1046-1054 (2013)
54. Lencioni R, Llovet JM. Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): Phase II, randomized, double-blind SPACE trial. J. Clin. Oncol. 30(Suppl. 4), Abstract LBA154 (2012)
55. Bolondi L, Piscaglia F. Yttrium 90 radioembolization: the horizon is changing for patients with intermediate and advanced hepatocellular carcinoma. Hepatology doi.org/10.1002/hep.26154 (2012) (Epub ahead of print
56. Mazzaferro V, Sposito C, Bhoori S et al. Yttrium(90) radioembolization for intermediate-advanced hepatocarcinoma: a Phase II study. Hepatology doi:10.1002/ hep.26014 (2012) (Epub ahead of print
57. Cabibbo G, Compilato D, Genco C, Campisi G. Extrahepatic spread of hepatocellular carcinoma. Panminerva Med. 54(4), 313-322 (2012)
58. Zhu AX. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist 11(7), 790-800 (2006)
59. Cabibbo G, Latteri F, Antonucci M, Craxi A. Multimodal approaches to the treatment of hepatocellular carcinoma. Nat. Clin. Pract. Gastroenterol. Hepatol. 6(3), 159-169 (2009)
60. Peng ZW, Zhang YJ, Chen MS et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J. Clin. Oncol. 31(4), 426-432 (2013)
61. Masuzaki R, Yoshida H, Omata M. Does chemotherapy prevent HCV-related hepatocellular carcinoma? Pros. Dig. Liver Dis. 42(Suppl. 3), S281-S286 (2010)
62. Llovet JM, Sala M, Castells L et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 31(1), 54-58 (2000)
63. Yamasaki S, Hasegawa H, Kinoshita H et al. A prospective randomized trial of the preventive effect of pre-operative transcatheter arterial embolization against recurrence of hepatocellular carcinoma. Jpn. J. Cancer Res. 87(2), 206-211 (1996
64. Muto Y, Moriwaki H, Ninomiya M et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N. Engl. J. Med. 334(24), 1561-1567 (1996
65. Cabibbo G, Maida M, Genco C, Antonucci M, Cammà C. Causes of and prevention strategies for hepatocellular carcinoma. Semin. Oncol. 39(4), 374-383 (2012)
66. Cammà C, Cabibbo G, Bronte F et al. Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C nonresponders to interferon plus ribavirin: a meta-analysis. J. Hepatol. 51(4), 675-681 (2009)
67. Cabibbo G, Rolle E, De Giorgio M et al.; HCC Working Group. Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib. Expert Rev. Anticancer Ther. 11(12), 1807-1816 (2011)
68. Cabibbo G, Palmeri L, Palmeri S, Craxì A. Should cirrhosis change our attitude towards treating non-hepatic cancer? Liver Int. 32(1), 21-27 (2012)
69. Villanueva A, Toffanin S, Llovet JM. Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. Curr. Opin. Oncol. 20(4), 444-453 (2008)
70. Siegel AB, Olsen SK, Magun A, Brown RS Jr. Sorafenib: where do we go from here? Hepatology 52(1), 360-369 (2010)
71. Siegel AB, Cohen EI, Ocean A et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J. Clin. Oncol. 26(18), 2992-2998 (2008)
72. Zhu AX, Blaszkowsky LS, Ryan DP et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 24(12), 1898-1903 (2006)
73. Thomas MB, Morris JS, Chadha R et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J. Clin. Oncol. 27(6), 843-850 (2009)
74. Faivre S, Raymond E, Boucher E et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, Phase II study. Lancet Oncol. 10(8), 794-800 (2009)
75. Zhu AX, Sahani DV, Duda DG et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a Phase II study. J. Clin. Oncol. 27(18), 3027-3035 (2009)
76. Cheng A, Kang D. Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC). J. Clin. Oncol. 29, Abstract 4000 (2011)
77. Garattini S, Bertele' V. Non-inferiority trials are unethical because they disregard patients' interests. Lancet 370(9602), 1875-1877 (2007)
78. Toh H, Chen P, Carr BI et al. A Phase II study of ABT-869 in hepaocellular carcinoma (HCC): interim analysis. J. Clin. Oncol. 27, Abstract 4581 (2009)
79. Gupta N, Chiu Y, Toh HC et al. Preliminary pharmacokinetics and safety comparison of Child-Pugh A vs. Child- Pugh B patients enrolled in a Phase 2 study of Linifanib (ABT-869) in Hepatocellular Carcinoma [Abstract]. ESMO 237 (2010)
80. Philip PA, Mahoney MR, Allmer C et al. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J. Clin. Oncol. 23(27), 6657-6663 (2005)
81. Thomas MB, Chadha R, Glover K et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 110(5), 1059-1067 (2007)
82. Rizell M, Andersson M, Cahlin C, Hafström L, Olausson M, Lindnér P. Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int. J. Clin. Oncol. 13(1), 66-70 (2008)
83. Huynh H, Chow KH, Soo KC et al. RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma. J. Cell. Mol. Med. 13(7), 1371-1380 (2009)
84. Zhu AX, Gold PJ, El-Khoueiry AB et al. First-in-man Phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin. Cancer Res. 19(4), 920-928 (2013)
85. Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology 140(5), 1410-1426 (2011)
86. Andrew XZ, Ian C, Jean-Frédéric B et al. A multicenter, randomized, double-blind, Phase III study of ramucirumab (IMC- 1121B; RAM) and best supportive care (BSC) versus placebo (PBO) and BSC as second-line treatment in patients (pts) with hepatocellular carcinoma (HCC) following first-line therapy with sorafenib (SOR). J. Clin. Oncol. 30, Abstract TPS4146 (2012)
87. ClinicalTrials.gov. Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM). www.clinicaltrials.gov/ct2/show/ NCT006 92770?term=storm+hcc&rank=1
88. ClinicalTrials.gov. First Line Hepato Cellular Carcinoma (HCC) (BRISK FL). http://clinicaltrials.gov/show/ NCT00858871
89. ClinicalTrials.gov. Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC). http://clinicaltrials.gov/ct2/show/ NCT010 09593?term=ABT+linifanib+HCC&ra nk=1
90. ClinicalTrials.gov. Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma (SEARCH). http://clinicaltrials.gov/ct2/show/NCT00 901901?term=erlotinib+sorafenib+hcc+III &rank=1
91. ClinicalTrials.gov. Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma). http://clinicaltrials.gov/ct2/show/NCT009 76170?term=GC33+HCC+sorafenib&ra nk=1
92. ClinicalTrials.gov. Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment (BRISK PS). www.clinicaltrials.gov/ct2/show/NCT008 25955?term=brivanib+and+HCC&rank=5